{
 "topic": "Beckwith-Wiedemann Syndrome",
 "slug": "beckwith-wiedemann-syndrome",
 "category_id": 15209,
 "summary": "An overgrowth and imprinting disorder of chromosome 11p15 causing macrosomia, macroglossia, and a marked predisposition to embryonal tumors that requires structured surveillance.",
 "written_by": "claude-sonnet",
 "references": [
  {
   "title": "Cover",
   "author": "Vitalsource Download",
   "pages": [
    6337,
    6523,
    8344
   ]
  },
  {
   "title": "Netters Pediatrics (Florin \u0422., Ludwig St.)",
   "author": null,
   "pages": [
    784
   ]
  },
  {
   "title": "Kliegman R. Nelson Textbook of Pediatrics 2-Volume Set 22ed 2024",
   "author": null,
   "pages": [
    1031,
    1035
   ]
  },
  {
   "title": "Zitelli and Davis' Atlas of Pediatric Physical Diagnosis: Expert Consult - Online",
   "author": null,
   "pages": [
    41
   ]
  },
  {
   "title": "Pediatric Nutrition (Ronald E. Kleinman, Frank R. Greer)",
   "author": null,
   "pages": [
    906
   ]
  },
  {
   "title": "MedStudy Pediatrics Core 11th Edition 2024-2025",
   "author": null,
   "pages": [
    378,
    613
   ]
  },
  {
   "title": "Gomella's Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs, Eighth Edition",
   "author": "Tricia Lacy Gomella, Fabien G. Eyal and Fayez Bany-Mohammed",
   "pages": [
    894
   ]
  },
  {
   "title": "CURRENT Diagnosis and Treatment Pediatrics, Twenty-Fourth Edition",
   "author": "Hay, William W., Levin, Myron J., Deterding, Robin R., Abzug, Mark J.",
   "pages": [
    1148
   ]
  }
 ],
 "short": [
  {
   "title": "In short",
   "content": "- Beckwith-Wiedemann syndrome (BWS) is an overgrowth/imprinting disorder of the 11p15 region, occurring in roughly 1 in 14,000 births, making it the most common overgrowth syndrome.\n- Core features: macrosomia, macroglossia, hemihyperplasia (lateralized overgrowth), omphalocele or umbilical hernia, visceromegaly (including nephromegaly and hepatosplenomegaly), and characteristic linear ear creases or pits.\n- Neonatal hypoglycemia is common, driven by pancreatic beta-cell hyperplasia; hyperinsulinism occurs in about 50% of BWS infants, is usually mild, and typically resolves within the first several weeks of life.\n- Most hyperinsulinism in BWS responds to diazoxide, but children with paternal uniparental isodisomy of 11p can have severe, persistent, diazoxide-unresponsive hyperinsulinism, sometimes needing lifelong treatment.\n- Genetics: over 50% of cases involve imprinting defects at 11p15.5 (methylation abnormalities of KCNQ1OT1/LIT1 in 50-60%, H19 in 2-7%), about 20% are from paternal uniparental disomy, and CDKN1C mutations account for 40% of familial and 5-10% of nonfamilial cases.\n- BWS carries a marked predisposition to embryonal tumors \u2014 chiefly Wilms tumor, hepatoblastoma, and adrenocortical carcinoma \u2014 with hepatoblastoma risk reported as roughly 2280-fold that of the general population; overall tumor risk is estimated near 7.5%, concentrated in the first 8 years of life.\n- Isolated hemihyperplasia is considered a mild, mosaic form of BWS and also carries increased embryonal tumor risk; combined BWS and hemihyperplasia carries the highest risk, estimated at 30-40%.\n- Standard tumor surveillance is serum alpha-fetoprotein (AFP) every 3 months (commonly until age 4, per one protocol) plus abdominal ultrasound every 3 months until age 8, with an international consensus statement (2018) tailoring the protocol to the specific underlying genetic mechanism.\n- Diagnosis is confirmed by demonstrating the abnormal 11p15 methylation pattern (e.g., of the LIT1/KCNQ1OT1 region) or another causative molecular defect; all patients should also be screened for nephrourological malformations at diagnosis."
  }
 ],
 "long": [
  {
   "title": "Definition",
   "content": "Beckwith-Wiedemann syndrome (BWS) is an overgrowth disorder caused by epigenetic and genetic disturbances of imprinted genes on chromosome 11p15, including those encoding IGF-2, H19, CDKN1C (p57KIP2), and KCNQ1. It is the most common overgrowth syndrome, occurring in approximately 1 in 14,000 births."
  },
  {
   "title": "Etiology",
   "content": "BWS arises from disruption of the imprinted 11p15.5 region. More than half of cases involve imprinting (methylation) defects: abnormal methylation of KCNQ1OT1 (LIT1), the differentially methylated region 2, is found in 50-60% of cases, while loss of methylation at H19 (differentially methylated region 1) accounts for 2-7%. About 20% of cases result from paternal uniparental disomy of 11p. Mutations in CDKN1C, a growth-regulating gene in this region, are found in about 40% of familial cases but only 5-10% of nonfamilial (sporadic) cases. Isolated hemihyperplasia, a partial or mosaic overgrowth confined to tissues, organs, or body segments, is considered a mild form of BWS that differs mainly in the relatively mosaic distribution of the methylation abnormality."
  },
  {
   "title": "Clinical features",
   "content": "Classic features include macrosomia (high birth weight), macroglossia \u2014 BWS is the most common cause of macroglossia in children \u2014 hemihyperplasia (lateralized overgrowth, which may be present at birth or develop over time), visceromegaly including nephromegaly and hepatosplenomegaly, and anterior abdominal wall defects such as omphalocele, umbilical hernia, or diastasis recti. Additional perinatal findings include polyhydramnios, prematurity, and characteristic craniofacial features such as linear ear creases or pits. Neonatal hypoglycemia is frequent and clinically important, caused by pancreatic beta-cell hyperplasia driving excess insulin production; hyperinsulinism affects roughly half of infants with BWS, though most cases are mild and resolve within the first several weeks of life."
  },
  {
   "title": "Diagnostics",
   "content": "Clinical diagnosis rests on a set of major and minor features, including macrosomia, hemihyperplasia, organomegaly, typical ear creases, hypoglycemia at birth, and embryonal tumors. Molecular confirmation demonstrates the abnormal methylation pattern of the 11p15 region (for example, of the LIT1/KCNQ1OT1 gene) or another causative genetic mechanism (CDKN1C mutation or paternal uniparental disomy). At diagnosis, all patients with BWS should be screened for nephrourological malformations by clinical evaluation and renal ultrasound."
  },
  {
   "title": "Differential diagnosis",
   "content": "Isolated hemihyperplasia without other BWS features is distinguished mainly by its more mosaic methylation pattern and is managed with the same tumor surveillance as BWS because of its own increased embryonal tumor risk. Sotos syndrome (cerebral gigantism) is another overgrowth condition, causing rapid early childhood growth, but without an associated endocrine disorder; most cases are sporadic, though autosomal dominant or recessive familial patterns occur. Macroglossia in a child should also prompt consideration of trisomy 21, congenital hypothyroidism, vascular malformations (lymphangioma or hemangioma of the tongue), muscular enlargement, or tumor."
  },
  {
   "title": "Complications",
   "content": "The central complication of BWS is a marked predisposition to embryonal tumors, particularly Wilms tumor, hepatoblastoma, and adrenocortical carcinoma. A national registry found the risk of hepatoblastoma in children with BWS to be 2280-fold higher than the general population, significantly higher than for any other tumor type in this group. The overall estimated tumor risk in BWS is about 7.5%, concentrated in the first 8 years of life, with tumor development uncommon after age 8; children with both BWS and hemihyperplasia have the highest risk, estimated at 30-40%. Serum AFP is markedly elevated with hepatoblastoma and is useful both for diagnosis and for monitoring for recurrence after treatment; with complete resection and postoperative chemotherapy, survival approaches 50%, and liver transplantation has been used successfully when complete resection is not possible. Hyperinsulinism, when caused by paternal uniparental isodisomy of 11p, can be severe, persistent, and unresponsive to diazoxide."
  },
  {
   "title": "Treatment",
   "content": "Neonatal hyperinsulinemic hypoglycemia in BWS is typically responsive to diazoxide and, in most infants, resolves within the first several weeks of life. Children with paternal uniparental isodisomy of 11p who have severe, diazoxide-unresponsive hyperinsulinism may require alternative management, and some individuals need diazoxide treatment into adulthood, possibly lifelong. Structured tumor surveillance is central to long-term management: recommended protocols include serum AFP every 3 months (through roughly age 3-4 years, depending on the protocol used) and abdominal ultrasound every 3 to 4 months until about age 7-8 years, with a 2018 international consensus statement recommending that the specific protocol be tailored to the underlying genetic or epigenetic mechanism. Early detection of malignancy through this surveillance significantly improves outcomes."
  }
 ],
 "clinical": [
  {
   "title": "Bedside recognition and immediate management",
   "content": "In a newborn with macrosomia, macroglossia, an omphalocele or umbilical hernia, hemihyperplasia, visceromegaly, or characteristic linear ear creases, check blood glucose promptly and monitor closely, since neonatal hypoglycemia from pancreatic beta-cell hyperplasia is common and clinically important in BWS. Hyperinsulinism affects about half of BWS infants; most cases are mild, resolve within the first several weeks of life, and respond to diazoxide. If hypoglycemia proves severe or persistent and unresponsive to diazoxide, consider paternal uniparental isodisomy of 11p as the underlying mechanism, which can require treatment into adulthood or lifelong. At diagnosis, screen for nephrourological malformations with clinical evaluation and renal ultrasound."
  },
  {
   "title": "Tumor surveillance",
   "content": "Because of the marked predisposition to embryonal tumors \u2014 chiefly Wilms tumor, hepatoblastoma, and adrenocortical carcinoma, with hepatoblastoma risk reported at roughly 2280-fold the general population \u2014 children with BWS require structured, ongoing surveillance rather than a one-time workup. Recommended monitoring is serum alpha-fetoprotein every 3 months (protocols describe this through age 3-4 years) together with abdominal ultrasound every 3 to 4 months until about age 7-8 years; one source describes AFP and abdominal/renal sonograms every 4 months for a child under surveillance. A 2018 international consensus statement recommends tailoring the exact surveillance protocol to the specific genetic or epigenetic mechanism identified. Because tumor risk is concentrated in the first 8 years of life and uncommon thereafter, surveillance can generally be relaxed beyond that age. An elevated or rising AFP or an abnormal ultrasound finding warrants prompt further evaluation, since early detection at an earlier tumor stage significantly improves outcomes."
  }
 ]
}